Navigation Links
Vion Pharmaceuticals to Present Survival Data on Laromustine at ASH Annual Meeting
Date:12/4/2008

Company Introduces New Trade Name Onrigin(TM) for Laromustine

NEW HAVEN, Conn., Dec. 4 /PRNewswire-FirstCall/ -- VION PHARMACEUTICALS, INC. (OTC Bulletin Board: VION) today made several announcements related to events in connection with the 50th American Society of Hematology Annual Meeting at the Moscone Center in San Francisco from December 6-9, 2008.

Vion Poster Presentation

The Company announced that it would present survival data for its lead anticancer product laromustine in a poster presentation.

    Title:      "Survival After Complete Response to Treatment with
                  Laromustine (Cloretazine(R)) in Elderly Patients with Poor
                  Risk Acute
                 Myelogenous Leukemia"
    Date:        Saturday, December 6
    Time:        9:30 a.m. to 7:30 p.m. (authors present 5:30-7:30 p.m.)
    Location:    Moscone Center Hall A, Board I-45

New Trade Name for Laromustine

Vion will introduce Onrigin(TM) as the new trade name for laromustine at the Meeting, replacing Cloretazine(R) (VNP40101M).

Vion Co-Sponsors Seminar on Acute Myelogenous Leukemia in Elderly Patients

The Company is co-sponsoring a seminar at the Meeting, in conjunction with MGI Pharmaceuticals and the Geriatric Oncology Consortium, entitled "Treating AML/MDS in the Elderly: New Solutions for a Long-Standing Problem." The seminar will take place in Rooms 3009, 3011, 3022 and 3024 on Friday, December 5 from 12:30 p.m. to 4:30 p.m. at the Moscone Center West.

Other Posters Related to Laromustine and Triapine(R)

The Company announced that additional posters presented by investigators would be made on laromustine and Triapine(R), its second anticancer agent in
'/>"/>

SOURCE Vion Pharmaceuticals, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related biology technology :

1. Vion Pharmaceuticals Pays Interest on 7.75% Convertible Senior Notes
2. China Biopharmaceuticals Holdings Announces Second Quarter 2007 Financial Results
3. Vion Pharmaceuticals Completes Accrual of 85 Patients to its Pivotal Phase II Trial of Cloretazine(R) (VNP40101M) in Elderly AML
4. XTL Biopharmaceuticals Announces Financial Results for the Six Months Ended June 30, 2007
5. Cadence Pharmaceuticals Reports Second Quarter 2007 Financial Results
6. Nabi Biopharmaceuticals to Present at Upcoming Industry Conferences
7. Anadys Pharmaceuticals Appoints Steve Worland, Ph.D. as President and Chief Executive Officer
8. Poniard Pharmaceuticals Announces Participation in Upcoming Conferences
9. NovaQuest Advances Virtual Development Model With Strategic Investment in TOPIGEN Pharmaceuticals
10. Drug Royalty Corporation (DRC) Announces Acquisition Regarding PEG-INTRON(R) From Enzon Pharmaceuticals, Inc. (ENZN)
11. Sunesis Pharmaceuticals Announces Reorganization to Focus Resources and Build Value in Clinical-Stage Programs
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:9/30/2014)... Mass. Using a bio-mimicking analog of one ... grass, an international research team led by Alejandro ... taken a major step in developing long-sought polymer ... electricity for use in electronic devices. , ... Amherst and others at Stanford University and Dresden ...
(Date:9/30/2014)... September 30, 2014 Shimadzu Scientific ... an easy-to-use and highly precise tool for measuring ... considerable elongation. With 1000-mm maximum movement distance, the ... for a gauge length of 10 mm. In ... accuracy above 50-mm stroke and within +/- 100 ...
(Date:9/30/2014)... 30, 2014 Proove Biosciences , ... excited to announce a new genetic test built upon ... Pain Perception Test will provide physicians with an ... pain tolerance levels are stratified between individuals. With this ... a person has a genetic predisposition that will affect ...
(Date:9/30/2014)... , Sept. 30, 2014 CORD:USE Cord Blood ... announce that it has entered into an Equity and ... which has licensed a series of patented technologies for the ... possible clinical applications.  Tianhe is performing Phase I/II clinical ... Spain using Tianhe,s Stem Cell Educator ...
Breaking Biology Technology:Blades of grass inspire advance in organic solar cells 2Blades of grass inspire advance in organic solar cells 3Shimadzu’s New Long-Travel Extensometer Increases Precision for Soft Material Testing 2Proove Biosciences is Now Offering the Proove Pain Perception Genetic Test to Help Physicians Assess Patient Pain Tolerance Levels 2Proove Biosciences is Now Offering the Proove Pain Perception Genetic Test to Help Physicians Assess Patient Pain Tolerance Levels 3CORD:USE is Pleased to Announce it has Partnered with Tianhe Stem Cell Biotechnologies, Developer of Cord Blood Stem Cell Therapy Showing Promising Results in Clinical Trials for the Treatment of Diabetes and Autoimmune Diseases 2CORD:USE is Pleased to Announce it has Partnered with Tianhe Stem Cell Biotechnologies, Developer of Cord Blood Stem Cell Therapy Showing Promising Results in Clinical Trials for the Treatment of Diabetes and Autoimmune Diseases 3CORD:USE is Pleased to Announce it has Partnered with Tianhe Stem Cell Biotechnologies, Developer of Cord Blood Stem Cell Therapy Showing Promising Results in Clinical Trials for the Treatment of Diabetes and Autoimmune Diseases 4
... second can make the difference between life and death, ... sensors" that allow for faster response times from military ... NC State that will help ensure those sensors will ... Afghanistan or elsewhere. "We,ve taken a sensor material ...
... ... of 2007 and to enhance patient safety with complete part traceability, can now use ... coding, scan and software tracking of each part and batch, including all leak test, ... ...
... the pleasantness of novel odors, just like a human ... notion that smell is completely personal and culture-specific. The ... Wolfson Medical Center, argue that the perception of an ... and it is only within specific contexts that personal ...
Cached Biology Technology:InterTech Development Company UDI System Announced 2Odor pleasantness shown to be partly hard-wired 2Odor pleasantness shown to be partly hard-wired 3
(Date:10/1/2014)... to take a healthy salad up a level by ... cancer in leafy greens. , "In the long run, ... eating the salad or making a pill from the ... engineering at Case Western Reserve School of Medicine and ... breast cancer organization is funding the research with a ...
(Date:9/30/2014)... each year, but its deep-blue waters host the ... alien species, including fish, crustaceans, and algae are ... In the open-access journal Frontiers in Marine ... data from a new information system developed by ... of alien species has changed the native biodiversity ...
(Date:9/30/2014)... Ocean Health Index rates the Earth,s oceans at ... addition, for the first time, the report assessed ... national jurisdiction (high-seas areas) all critical regions ... providing sustainable food sources. , In the third ... by scientists from UC Santa Barbara,s National Center ...
Breaking Biology News(10 mins):Scientists wield plant viruses against deadly human disease 2Scientists wield plant viruses against deadly human disease 3Biodiversity in the Mediterranean is threatened by alien species 2Rating the planet's oceans 2Rating the planet's oceans 3
... new map of the potato genome that may lead ... help feed the world,s hungry. By sequencing and ... consortium has, for the first time, tied specific potato ... and development of potatoes may enable scientists and breeders ...
... Institute, one of the National Institutes of Health, has ... of Medicine each approximately $2.3 million a year for ... Glycosciences. Gerald Hart, Ph.D., director of biological chemistry and ... will lead these independent efforts to better understand the ...
... TORONTO, Ont., July 12, 2001--Eating nuts every day could ... according to new research from St. Michael,s Hospital and ... online by the journal Diabetes Care , a ... of Toronto Department of Nutritional Sciences; St. Michael,s Hospital ...
Cached Biology News:Johns Hopkins researchers awarded $32 million 2A 'nutty' solution to type 2 diabetes management 2